You are here
Qrono, Inc.
DUNS: 055292329
# of Employees: 2
HUBZone Owned: Y
Socially and Economically Disadvantaged: N
Woman Owned: N
Award Charts
Award Listing
-
IGF OT IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER
Amount: $1,498,252.00Proposed is a continued development of QR which comprises epothilone D EpoD a highly toxic chemotherapy in its free form reformulated into long acting poly lactic co glycolic acid micropartic ...
SBIRPhase II2016Department of Health and Human Services -
Computationally designed adjuvant platform enhancing dengue vaccine immunogenicity
Amount: $99,999.00Dengue fever incidence has grown exponentially over the past 50 years and now causes disease in nearly 100 million people annually. Vaccination offers the most effective method of protecting at-risk i ...
SBIRPhase I2015Department of Defense Army -
Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.
Amount: $998,670.00Elevated levels of human butyrylcholinesterase (hBuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protect ...
SBIRPhase II2014Department of Defense Office for Chemical and Biological Defense -
Title: Failed tubulin inhibitor reformulated as localized adjuvant therapy for head and neck cancer POP: 09/12/2014-06/11/2015
Amount: $223,412.00Qrono's long-term oncology goal is to revolutionize cancer treatment with safer, more efficacious chemotherapy formulations. Qrono has created a new drug delivery platform by mathematically optim ...
SBIRPhase I2014Department of Health and Human Services -
Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.
Amount: $99,575.00Elevated levels of human butyrylcholinesterase (BuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protecti ...
SBIRPhase I2013Department of Defense Office for Chemical and Biological Defense -
A New In Silico Design Platform for Building Custom Controlled Release Systems
Amount: $256,217.00DESCRIPTION (provided by applicant): Controlled release formulations can improve patient adherence and drug safety or even enable new types of basic medical research. The key to realizing these benefi ...
STTRPhase I2013Department of Health and Human Services
